Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease

Completed

• Conditions: Chronic Obstructive Pulmonary Disease; Chronic Heart Failure

• Registration Number: NCT01801722
• Lead Sponsor: Lund University

Brief Summary

The aim of the present study was to evaluate if the analysis of NT-proBNP might be used as an initial step for the diagnosis of chronic heart failure in patients with COPD in primary health care, and to select patients for a further examination by echocardiography.

Detailed Description

Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure.

1. An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance.

2. Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema.

3. Electrocardiography.

4. Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden).

5. Patients with the NT-proBNP level of \> 1200 pg/ml were referred for echocardiography to assess left ventricular function.

Study Timeline

• Study Start: 2008-04
• Primary Completion: 2008-06
• Study Completion: 2008-06
• Study First Submitted: 2013-02-25
• Study First Submitted QC: 2013-02-28
• Study First Posted: 2013-03-01
• Status Verified: 2018-03
• Last Update Submitted: 2018-03-06
• Last Update Posted: 2018-03-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

• Patients aged 65 years and older with the following diagnosis codes according to International Statistical Classification of Diseases and Related Health Problems - Tenth Revision:J44 (COPD) and J41, J42 (chronic bronchitis) registered during the period 1 January 2008-16 April 2008 according to the electronic patient record.

Exclusion Criteria

• Impaired cognitive function and/or anticipated difficulties in carrying out spirometry due to immobility,
• psychiatric disorders or terminal illness.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percentage of patients with elevated NT-proBNP.	3 months	NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.

Secondary Outcome Measures

Name	Time	Method
Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography.	3 months	Echocardiography was performed once in each referred patient. Three months was a period of data collection.

Trial Locations

Locations (1)

Primary health care center.; 🇸🇪 Olofström, Blekinge, Sweden